var data={"title":"Sodium phosphate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium phosphate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6970?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sodium-phosphate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phosphate: Drug information&quot;</a> and <a href=\"topic.htm?path=sodium-phosphate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sodium phosphate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7688983\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephropathy (tablet): </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">There have been rare but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin-converting enzyme [ACE] inhibitors, angiotensin receptor blockers, and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).</p>\n        <p style=\"text-indent:0em;\">It is important to use the dose and dosing regimen as recommended (PM/AM split dose).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221976\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Fleet Enema Extra [OTC];</li>\n      <li>Fleet Enema [OTC];</li>\n      <li>Fleet Pedia-Lax Enema [OTC];</li>\n      <li>LaCrosse Complete [OTC];</li>\n      <li>OsmoPrep</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221977\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Fleet Enema</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1036259\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Oral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Electrolyte Supplement, Parenteral</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Laxative, Saline</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Sodium Salt</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445047\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If phosphate repletion is required and a phosphate product is not available at your institution, consider the use of sodium glycerophosphate pentahydrate (Glycophos) as a suitable substitute. Concentration and dosing are different from FDA approved products; use caution when switching between products. Refer to sodium glycerophosphate pentahydrate monograph.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Caution: With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement.</b> The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. Intravenous doses listed as mmol of phosphate. <b>Note:</b> Consider the contribution of sodium when determining the appropriate phosphate replacement.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Phosphorus Estimated Average Requirement (EAR):</b> Dietary Intake Reference (DIR) (1997 National Academy of Science Recommendations) (<b>Note:</b> DIR is under review as of March 2009): Oral: 3.2 mmol/day (adequate intake)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parenteral nutrition, maintenance requirement</b> (Mirtallo 2004): IV: 1 to 2 mmol/kg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1036284\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=sodium-phosphate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phosphate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> If phosphate repletion is required and a phosphate product is not available at your institution, consider the use of sodium glycerophosphate pentahydrate (Glycophos) as a suitable substitute. Concentration and dosing are different from FDA approved products; use caution when switching between products. Refer to sodium glycerophosphate pentahydrate monograph.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Caution: With orders for IV phosphate, there is considerable confusion associated with the use of millimoles (mmol) versus milliequivalents (mEq) to express the phosphate requirement. </b>The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. Intravenous doses listed as mmol of phosphate. <b>Note:</b> Consider the contribution of sodium when determining the appropriate phosphate replacement.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infants, Children, and Adolescents: Phosphorus: Oral: See table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Phosphorus &minus; Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR)</caption>\n      <col></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">Age</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">RDA</p>\n            <p style=\"text-indent:0em;\">(mmol/day)</p></th>\n          <th valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\">EAR</p>\n            <p style=\"text-indent:0em;\">(mmol/day)</p></th></tr></thead>\n      <tfoot valign=\"top\">\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <sup>A</sup>Adequate intake (AI)</p></td></tr></tfoot>\n      <tbody valign=\"top\">\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1-6 mo</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3.2<sup>A</sup></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">7-12 mo</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&minus;</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">8.9<sup>A</sup></p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1-3 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">14.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.3</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">4-8 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">16.1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">13.1</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">9-18 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40.3</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">19-30 y</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">22.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18.7</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hypophosphatemia, acute:</b> Hypophosphatemia does not necessarily equate with phosphate depletion. Hypophosphatemia may occur in the presence of low, normal, or high total body phosphate and conversely, phosphate depletion may exist with normal, low, or elevated levels of serum phosphate (Gaasbeek 2005). It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. Intermittent IV infusion should be reserved for severe depletion situations; requires continuous cardiac monitoring. Guidelines differ based on degree of illness, need/use of TPN, and severity of hypophosphatemia. If hypokalemia exists, consider phosphate replacement strategy with potassium (eg, potassium phosphates). Various regimens for replacement of phosphate in adults have been studied. The regimens below have only been studied in adult patients; however, many institutions have used them in children safely and successfully. Obese patients and/or severe renal impairment were excluded from phosphate supplement trials. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">IV doses may be incorporated into the patient's maintenance IV fluids; intermittent IV infusion should be reserved for severe depletion situations. <b>Note:</b> Doses listed as mmol of <b>phosphate</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: <b>Note:</b> There are no prospective studies of parenteral phosphate replacement in children. The following weight-based guidelines for adult dosing may be cautiously employed in pediatric patients. Guidelines differ based on degree of illness, use of TPN, and severity of hypophosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>General replacement guidelines</i> (Lentz 1978): <b>Note:</b> The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 0.08 mmol/kg over 6 hours; use if losses are recent and uncomplicated</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate dose: 0.16 to 0.24 mmol/kg over 4 to 6 hours; use if serum phosphorus level 0.5 to 1 mg/dL (0.16 to 0.32 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: 0.36 mmol/kg over 6 hours; use if serum phosphorus &lt;0.5 mg/dL (&lt;0.16 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Patients receiving TPN</i> (Clark 1995):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 0.16 mmol/kg over 4 to 6 hours; use if serum phosphorus level 2.3 to 3 mg/dL (0.73 to 0.96 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate dose: 0.32 mmol/kg over 4 to 6 hours; use if serum phosphorus level 1.6 to 2.2 mg/dL (0.51 to 0.72 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: 0.64 mmol/kg over 8 to 12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Critically ill adult trauma patients receiving TPN</i> (Brown 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 0.32 mmol/kg over 4 to 6 hours; use if serum phosphorus level 2.3 to 3 mg/dL (0.73 to 0.96 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate dose: 0.64 mmol/kg over 4 to 6 hours; use if serum phosphorus level 1.6 to 2.2 mg/dL (0.51 to 0.72 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose: 1 mmol/kg over 8 to 12 hours; use if serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;margin-top:2em;\">\n      <i>Alternative method in critically ill patients</i> (Kingston 1985):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose: 0.25 mmol/kg over 4 hours; use if serum phosphorus level 0.5 to 1 mg/dL (0.16 to 0.32 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate dose: 0.5 mmol/kg over 4 hours; use if serum phosphorus level &lt;0.5 mg/dL (&lt;0.16 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Maintenance:</b> Oral: 2 to 3 mmol/kg/day in divided doses (including dietary intake)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Parenteral nutrition, maintenance requirement</b> (Mirtallo 2004): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children &le;50 kg: 0.5 to 2 mmol/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;50 kg and Adolescents: 10 to 40 mmol/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Constipation:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral, solution (Monobasic sodium phosphate monohydrate 2.4 g and dibasic sodium phosphate heptahydrate 0.9 g per 5 mL): <b>Note:</b> Must be diluted in a full glass of water:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 9 years: 7.5 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 10 to 11 years: 15 mL as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 15 mL as a single dose; maximum single daily dose: 45 mL/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rectal: Fleet Enema:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 4 years: Administer <b>one half</b> contents of one 2.25 ounce pediatric enema</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 11 years: Administer the contents of one 2.25 ounce pediatric enema</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Administer the contents of one 4.5 ounce enema as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypophosphatemia, acute treatment:</b> IV: It is difficult to provide concrete guidelines for the treatment of severe hypophosphatemia because the extent of total body deficits and response to therapy are difficult to predict. Aggressive doses of phosphate may result in a transient serum elevation followed by redistribution into intracellular compartments or bone tissue. It is recommended that repletion of severe hypophosphatemia be done IV because large doses of oral phosphate may cause diarrhea and intestinal absorption may be unreliable. Intermittent IV infusion should be reserved for severe depletion situations; requires continuous cardiac monitoring. Guidelines differ based on degree of illness, need/use of TPN, and severity of hypophosphatemia. If hypokalemia exists (some clinicians recommend threshold of &lt;4 mmol/L), consider phosphate replacement strategy with potassium (eg, potassium phosphates). Obese patients and/or severe renal impairment patients were excluded from phosphate supplement trials. <b>Note:</b> 1 mmol phosphate = 31 mg phosphorus; 1 mg phosphorus = 0.032 mmol phosphate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>General replacement guidelines</i> (Lentz 1978):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose, serum phosphorus losses are recent and uncomplicated: 0.08 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate dose, serum phosphorus level 0.5 to 1 mg/dL (0.16 to 0.32 mmol/L): 0.16 to 0.24 mmol/kg over 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The initial dose may be increased by 25% to 50% if the patient is symptomatic secondary to hypophosphatemia and lowered by 25% to 50% if the patient is hypercalcemic.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Critically ill adult patients receiving concurrent enteral/parenteral nutrition</i> (Brown 2006; Clark 1995): <b>Note:</b> Round doses to the nearest 7.5 mmol for ease of preparation. If administering with phosphate-containing parenteral nutrition, do not exceed 15 mmol/L within parenteral nutrition. May use adjusted body weight for patients weighing &gt;130% of ideal body weight (and BMI &lt;40 kg/m<sup>2</sup>) by using [IBW + 0.25 (ABW-IBW)]:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low dose, serum phosphorus level 2.3 to 3 mg/dL (0.74 to 0.96 mmol/L): 0.16 to 0.32 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intermediate dose, serum phosphorus level 1.6 to 2.2 mg/dL (0.51 to 0.71 mmol/L): 0.32 to 0.64 mmol/kg over 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High dose, serum phosphorus &lt;1.5 mg/dL (&lt;0.5 mmol/L): 0.64 to 1 mmol/kg over 8 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Parenteral nutrition:</b> IV: 10 to 15 mmol/1,000 kcal (Hicks 2001) <b>or</b> 20 to 40 mmol/24 hours (Mirtallo 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Laxative (Fleet):</b> Rectal: Contents of one 4.5 oz enema as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Laxative:</b> Oral solution: 15 mL as a single dose; maximum single daily dose: 45 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Bowel cleansing prior to colonoscopy:</b> Oral tablets: <b>Note:</b> Do not use additional agents, especially other sodium phosphate products.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>OsmoPrep:</i> A total of 32 tablets and 2 quarts of clear liquids (8 ounces of clear liquids with each dose) divided as follows:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Evening before colonoscopy: 4 tablets every 15 minutes for 5 doses (total of 20 tablets)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">3 to 5 hours prior to colonoscopy: 4 tablets every 15 minutes for 3 doses (total of 12 tablets)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221959\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution [concentrate; preservative free]: Phosphorus 3 mmol and sodium 4 mEq per 1 mL (5 mL, 15 mL, 50 mL) [equivalent to phosphorus 93 mg and sodium 92 mg per 1 mL; source of electrolytes: monobasic and dibasic sodium phosphate]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, oral: Monobasic sodium phosphate monohydrate 2.4 g and dibasic sodium phosphate heptahydrate 0.9 g per 5 mL (45 mL) [sugar free; contains sodium 556 mg/5 mL, sodium benzoate; ginger-lemon flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, rectal [enema]: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fleet Enema: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL) [contains sodium 4.4 g/118 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fleet Enema Extra: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 197 mL delivered dose (230 mL) [contains sodium 4.4 g/197 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fleet Pedia-Lax&trade; Enema: Monobasic sodium phosphate monohydrate 9.5 g and dibasic sodium phosphate heptahydrate 3.5 g per 59 mL delivered dose (66 mL) [contains sodium 2.2 g/59 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">LaCrosse Complete: Monobasic sodium phosphate monohydrate 19 g and dibasic sodium phosphate heptahydrate 7 g per 118 mL delivered dose (133 mL) [contains sodium 4.4 g/118 mL]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, oral [scored]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">OsmoPrep: Monobasic sodium phosphate monohydrate 1.102 g and dibasic sodium phosphate anhydrous 0.398 g [sodium phosphate 1.5 g per tablet; gluten free]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221943\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Enema, injection, oral solution</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21963743\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=sodium-phosphate-drug-information\" class=\"drug drug_general\">see &quot;Sodium phosphate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium 4 mEq is equivalent to sodium 92 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorous 3 mmol is equivalent to phosphorus 93 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874991\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">OsmoPrep:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135936.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQU13IidMiIFsD8wC4fzbSTA==&amp;TOPIC_ID=12987\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM135936.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1036290\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Maintain adequate fluid intake</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Constipation (oral solution): Take on an empty stomach; dilute dose in 8 ounces of cool water, follow with an additional 8 ounces of water; <b>do not repeat dose within 24 hours</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bowel cleansing (OsmoPrep): Administer each dose with at least 8 ounces of clear liquids; have patient rehydrate before and after colonoscopy. Clear liquids may include water, flavored water, pulp-free lemonade, ginger ale, or apple juice; purple or red colored liquids should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> In general, the dose, concentration of infusion, and rate of administration may be dependent on patient condition and specific institution policy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent IV infusion: Must be diluted in appropriate IV solution and volume prior to administration and infused slowly to avoid toxicity; in pediatric patients, suggested maximum concentrations used by some centers: Peripheral line: 0.05 mmol/mL; Central line: 0.12 mmol/mL (maximum concentrations were determined with consideration for maximum sodium concentration). Infusion of doses over 4 to 6 hours for mild/moderate hypophosphatemia or 8 to 12 hours for severe hypophosphatemia has been recommended (Brown 2006; Clark 1995; Lentz 1978); for adult patients with severe symptomatic hypophosphatemia (ie, &lt;1.5 mg/dL), may administer at rates up to 15 mmol phosphate/hour (Charron 2003; Rosen 1995). Do not infuse with calcium-containing IV fluids.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parenteral nutrition solution: Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. The pH of the solution is primarily dependent upon the amino acid concentration. The higher the percentage of amino acids the lower the pH, the more soluble the calcium and phosphate. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and subsequent calcium phosphate compatibility; consult product specific labeling for additional information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Gently insert enema tip into rectum with a slight side-to-side movement and tip pointing toward the navel; have patient bear down. Administer with patient lying on left side and knees bent or with patient kneeling and head and chest leaning forward until left side of face is resting comfortably. <b>Note:</b> Preparation for <b>one half</b> bottle administration: Unscrew cap and remove 30 mL of liquid; replace cap and administer as usual.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221974\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enema: Store at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution for injection: Store intact vials at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C and  30&deg;C (59&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and  30&deg;C (59&deg;F and 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1036260\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Treatment and prevention of hypophosphatemia; source of phosphate in large-volume IV fluids (FDA approved in all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: Treatment of occasional constipation (OTC product: FDA approved in ages &ge;5 years and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets (OsmoPrep): Bowel cleansing for colonoscopy (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rectal: Treatment of occasional constipation (OTC product: Fleet Pedia-Lax Enema: FDA approved in ages 2 to 11 years; Fleet Enema, Fleet Enema Extra: FDA approved in ages &ge;12 years and adults. Refer to product-specific information to determine FDA approved ages for additional products).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2931717\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enemas and oral solution are available in pediatric and adult sizes; prescribe by &ldquo;volume&rdquo; not by &ldquo;bottle.&rdquo;</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Because inorganic phosphate exists as monobasic and dibasic anions, with the mixture of valences dependent on pH, ordering by mEq amounts is unreliable and may lead to large dosing errors. In addition, IV phosphate is available in the sodium and potassium salt; therefore, the content of these cations must be considered when ordering phosphate. The most reliable method of ordering IV phosphate is by millimoles, then specifying the potassium or sodium salt. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221992\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, bloating, mucosal bleeding, nausea, superficial mucosal ulcerations, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Hypernatremia, hyperphosphatemia, hypocalcemia (on colonoscopy day), hypokalemia (on colonoscopy day), hypophosphatemia (2-3 days postcolonoscopy)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Acute phosphate nephropathy, anaphylaxis, bronchospasm, calcium nephrolithiasis, cardiac arrhythmia, dehydration, dysphagia, dyspnea, facial edema, increased blood urea nitrogen, increased serum creatinine, ischemic colitis, lip edema, paresthesia, pharyngeal edema, pruritus, rectal bleeding, renal failure, renal insufficiency, renal tubular necrosis, seizure, skin rash, tightness in throat, tongue edema, urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221965\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to sodium phosphate salts or any component of the formulation; additional contraindications vary by product:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Intravenous preparation: Diseases with hyperphosphatemia, hypocalcemia, or hypernatremia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablets: Acute phosphate nephropathy (biopsy proven), bowel obstruction, bowel perforation, gastric bypass or stapling surgery, toxic colitis, toxic megacolon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">OTC labeling (Oral Solution):  When used for self-medication: Dehydration, heart failure, renal impairment, electrolyte abnormalities; use for bowel cleansing, use in children &lt;5 years</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221947\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephropathy: <b>[US Boxed Warning]: Acute phosphate nephropathy (APN) has been reported (rarely) with use of oral products as a colon cleanser prior to colonoscopy. Some cases have resulted in permanent renal impairment (some requiring dialysis). Risk factors for acute phosphate nephropathy may include increased age (&gt;55 years of age), preexisting renal dysfunction, bowel obstruction, active colitis, or dehydration, and the use of medicines that affect renal perfusion or function (eg, ACE inhibitors, angiotensin receptor blockers, diuretics, and possibly NSAIDs), although some cases have been reported in patients without apparent risk factors.</b> Other preventive measures may include avoid exceeding maximum recommended doses and concurrent use of other laxatives containing sodium phosphate; encourage patients to adequately hydrate before, during, and after use; obtain baseline and postprocedure labs in patients at risk; consider hospitalization and intravenous hydration during bowel cleansing for patients unable to hydrate themselves (eg, frail patients). Use is contraindicated in patients with acute phosphate nephropathy (biopsy proven). APN has also been reported (rarely) following the use of sodium phosphate enemas. This has been primarily observed in elderly patients with and without preexisting renal impairment and with those receiving standard or doses exceeding usual doses (Ori 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: Prolongation of the QT interval has been reported (associated with hypokalemia, hypocalcemia).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular: Use caution in patients with heart failure (contraindicated with enema products), unstable angina, history of myocardial infarction arrhythmia, cardiomyopathy; use caution in patients with or at risk for arrhythmias (eg, cardiomyopathy, prolonged QT interval, history of uncontrolled arrhythmias, recent MI) or with concurrent use of other QT-prolonging medications; pre-/postdose ECGs should be considered in high-risk patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte disturbances: Use with caution in patients with pre-existing electrolyte imbalances, dehydration, or risk of electrolyte disturbance (hypocalcemia, hyperphosphatemia, hypernatremia). Correct dehydration prior to using for bowel preparations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disorders: Use caution in patients with any of the following: Gastric retention or hypomotility, ileus, severe, chronic constipation, or colitis. Use is contraindicated in patients with bowel obstruction (including pseudo) or perforation, congenital megacolon, gastric bypass or bariatric surgery, toxic colitis, or toxic megacolon.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Inflammatory bowel disease: Use with caution in patients with chronic inflammatory bowel disease or severe active ulcerative colitis; may induce colonic aphthous ulceration and ischemic colitis (some requiring hospitalization). Colitis has been associated with acute phosphate nephropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; patients may be at risk for sodium retention and edema. Close monitoring required to avoid hyperphosphatemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizures, those at higher risk of seizures or on medication that lowers seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bulimia nervosa patients: Laxatives and purgatives have the potential for abuse by bulimia nervosa patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; consider each patient's ability to hydrate properly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; ensure they are able to hydrate themselves if using for bowel preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impaired gag reflex: Use with caution in patients with impaired gag reflex and those prone to regurgitation or aspiration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Enemas/oral solutions: Available in pediatric and adult sizes; prescribe by &ldquo;volume&rdquo; not by &ldquo;bottle.&rdquo;</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel evacuation: Appropriate use: If using as a bowel evacuant, correct electrolyte abnormalities before administration. Ensure adequate clear liquid intake prior to and during bowel evacuation regimens; inadequate fluid intake may lead to excessive fluid loss and hypovolemia. Other oral medications may not be well absorbed when given during bowel evacuation because of rapid intestinal peristalsis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Constipation: Appropriate use: Rare but potentially serious adverse effects (including death) may occur when exceeding recommended doses of over-the-counter (OTC) sodium phosphate preparations to treat constipation. Severe dehydration and alterations in serum electrolytes (eg, calcium, sodium, phosphate) leading to renal/cardiac adverse effects have been reported, mostly when single maximum doses were exceeded or when more than 1 dose was taken per day. Patients should be advised to adhere to the product labeling and not exceed maximum recommended doses. Health care providers should use caution when recommending doses for oral sodium phosphate preparations for children younger than 5 years of age. Rectal preparations should never be administered to children younger than 2 years of age (FDA Drug Safety Communication, 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300067\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221952\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12987&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with ACEIs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration.  Separating administer of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Salts: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diuretics: May enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the absorption of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral iron salt as possible to minimize the significance of this interaction.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Salts: May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an oral magnesium salt as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Phosphate Supplements. Management: Administer oral phosphate supplements as far apart from the administration of an iron-containing oral multivitamin as possible to minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Sodium Phosphates may enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sucralfate: May decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Administering oral phosphate supplements at least 1 hour before or 2 hours after administration of sucralfate may reduce the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221954\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221968\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Reproduction studies have not been conducted with these products. Use with caution in pregnant women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1036293\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Serum sodium, calcium, and phosphorus concentrations; renal function; in pediatric patients after  IV phosphate repletion, repeat serum phosphorus concentration should be checked 2 hours later (ASPEN Pediatric Nutrition Support Core Curriculum, 2010) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Bowel cleansing: Baseline and postprocedure labs (electrolytes, calcium, phosphorus, BUN, creatinine) in patients at risk for acute renal nephropathy, seizure, or who have a history of electrolyte abnormality; ECG in patients with risks for prolonged QT or arrhythmias. Ensure euvolemia before initiating bowel preparation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rectal: Stool output </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3426716\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> There is a diurnal variation with the nadir at 1100, plateau at 1600, and peak in the early evening (Gaasbeek 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Newborn 0 to 5 days: 4.8 to 8.2 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1 to 3 years: 3.8 to 6.5 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">4 to 11 years: 3.7 to 5.6 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">12 to 15 years: 2.9 to 5.4 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">16 to 19 years: 2.7 to 4.7 mg/dL</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221946\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a laxative, exerts osmotic effect in the small intestine by drawing water into the lumen of the gut, producing distention and promoting peristalsis and evacuation of the bowel; phosphorous participates in bone deposition, calcium metabolism, utilization of B complex vitamins, and as a buffer in acid-base equilibrium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221964\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Cathartic: 3 to 6 hours; Rectal: 2 to 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: ~1% to 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral forms excreted in feces; IV forms are excreted in the urine with over 80% to 90% of dose reabsorbed by the kidney</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F221967\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (Enema Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7-19 g/118 mL (133 mL): $1.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (Fleet Enema Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7-19 g/118 mL (133 mL): $1.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Enema</b> (Fleet Pediatric Rectal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.5-9.5 g/59 mL (66 mL): $1.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sodium Phosphate-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mmol/100 mL (100 mL): $14.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mmol/100 mL (100 mL): $21.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15MMOL/250ML (250 mL): $23.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30MMOL/250ML (250 mL): $37.76</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Sodium Phosphates Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mmole/5ml (5 mL): $17.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mmole/15ml (15 mL): $17.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (OsmoPrep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.102-0.398 g (100): $800.30</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown KA, Dickerson RN, Morgan LM, et al, &ldquo;A New Graduated Dosing Regimen for Phosphorus Replacement in Patients Receiving Nutrition Support,&rdquo; <i>JPEN</i>, 2006, 30(3):209-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/ 16639067 /pubmed\" target=\"_blank\" id=\" 16639067 \"> 16639067 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Charron T, Bernard F, Skrobik Y, et al, &ldquo;Intravenous Phosphate in the Intensive Care Unit: More Aggressive Repletion Regimens for Moderate and Severe Hypophosphatemia,&rdquo; <i>Intensive Care Med</i>, 2003, 29(8):1273-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/12845429/pubmed\" target=\"_blank\" id=\"12845429\">12845429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark CL, Sacks GS, Dickerson RN, et al, &ldquo;Treatment of Hypophosphatemia in Patients Receiving Specialized Nutrition Support Using a Graduated Dosing Scheme: Results From a Prospective Clinical Trial,&rdquo; <i>Crit Care Med</i>, 1995, 23(9):1504-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/7664552/pubmed\" target=\"_blank\" id=\"7664552\">7664552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Department Health and Human Services, Food and Drug Administration, &quot;Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,&quot; <i>Federal Register</i>, 2000, 65(17):4103-11.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine,&rdquo; National Academy of Sciences, Washington, DC: National Academy Press, 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gaasbeek A and Meinders AE, &ldquo;Hypophosphatemia: An Update on Its Etiology and Treatment&rdquo;,<i> Am J Med</i>, 2005, 118(10):1094-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/16194637/pubmed\" target=\"_blank\" id=\"16194637\">16194637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kingston M and Al-Siba'i MB, &quot;Treatment of Severe Hypophosphatemia,&quot; <i>Crit Care Med</i>, 1985, 13(1):16-8<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/3965243/pubmed\" target=\"_blank\" id=\"3965243\">3965243</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lentz RD, Brown BM, and Kjellstrand CM, &ldquo;Treatment of Severe Hypophosphatemia,&rdquo; <i>Ann Intern Med</i>, 1978, 89(6):941-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/102230 /pubmed\" target=\"_blank\" id=\"102230 \">102230 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lloyd CW and Johnson CE, &ldquo;Management of Hypophosphatemia,&rdquo; <i>Clin Pharm</i>, 1988, 7(2):123-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/3280219/pubmed\" target=\"_blank\" id=\"3280219\">3280219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosen GH, Boullata JI, O'Rangers EA, et al, &ldquo;Intravenous Phosphate Repletion Regimen for Critically Ill Patients With Moderate Hypophosphatemia,&rdquo; <i>Crit Care Med</i>, 1995, 23(7):1204-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-phosphate-pediatric-drug-information/abstract-text/7600828/pubmed\" target=\"_blank\" id=\"7600828\">7600828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schmidt GL, &ldquo;Fluids and Electrolytes,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds, The A.S.P.E.N Pediatric Nutrition Support Core Curriculum, Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 87-102.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12987 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F7688983\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F221976\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F221977\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1036259\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445047\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1036284\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F221959\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F221943\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21963743\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874991\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1036290\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F221974\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1036260\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2931717\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F221992\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F221965\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F221947\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300067\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F221952\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F221954\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F221968\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1036293\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F3426716\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F221946\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F221964\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F221967\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12987|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sodium-phosphate-drug-information\" class=\"drug drug_general\">Sodium phosphate: Drug information</a></li><li><a href=\"topic.htm?path=sodium-phosphate-patient-drug-information\" class=\"drug drug_patient\">Sodium phosphate: Patient drug information</a></li></ul></div></div>","javascript":null}